- In January 2025, Boehringer Ingelheim Vietnam hosted its inaugural VAXXITEK symposium and unveiled the VAXXITEK HVT + IBD + ND poultry vaccine. This vaccine marks Vietnam's first vector vaccine that targets three diseases with a single dose: Marek's disease, Gumboro disease, and Newcastle disease. The vaccine technology focuses on achieving a balance between effectiveness and safety, which is essential in the development of the final product.
- In April 2024, Merck Animal Health announced that the European Medicines Agency's Committee for Veterinary Medicinal Products (CVMP) issued a positive opinion for the marketing authorization of the INNOVAX-ND-H5 vaccine under exceptional circumstances, as outlined in Article 25 of Regulation (EU) 2019/6. The vaccine is designed to reduce mortality, clinical symptoms, and virus excretion caused by infection with the highly pathogenic Avian Influenza (HPAI) virus of the H5 type. In addition, INNOVAX-ND-H5 provides active immunity against Marek’s disease and Newcastle disease.
- In August 2022, the Mount Sinai Health System in New York, NY, introduced CastleVax, Inc., a clinical-stage company focused on vaccine research and development. CastleVax is committed to the commercial advancement of the Newcastle disease virus (NDV) vaccine platform technology, originally developed by Peter Palese and his team. This platform utilizes Newcastle disease virus (NDV), a member of the avian paramyxovirus family (APMV), which is harmless to humans. It has been engineered to enable the creation of both intranasal and intramuscular vaccines targeting emerging SARS-CoV-2 variants, such as the Omicron variants, as well as a broad spectrum of other viral pathogens.
- In March 2022, a team of clinical researchers at the Icahn School of Medicine at Mount Sinai announced the initiation of a Phase 1, open-label, placebo-controlled study to assess the safety and immunogenicity of an egg-based COVID-19 vaccine in healthy, vaccinated adults who have never been infected with COVID-19. This vaccine, known as NDV-HXP-S, contains a recombinant Newcastle disease virus that expresses the SARS-CoV-2 spike protein, the virus responsible for COVID-19. It is free from adjuvants and preservatives, and may offer the potential for enhanced immunity against COVID-19.
- In January 2021, Zoetis announced the expansion of its recombinant vector vaccine portfolio with the introduction of Poulvac Procerta HVT-IBD. This vaccine offers early protection against the current infectious bursal disease (IBD) viruses affecting U.S. broiler flocks. Poulvac Procerta HVT-IBD is an essential tool for managing IBD, providing significant protection and offering early defense against IBD viruses, including the dominant AL2 variant.
